Biolyst › CYTKCYTOKINETICS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 7, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 24 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 36 concluded trials, 78% reached completion rather than being terminated or withdrawn.
Track CYTK alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CYTK in the tracker
Recent history
Date Event Type Phase
September 15, 2026
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF Trial Milestone
Phase 2
August 31, 2026
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) Trial Milestone
Phase 3
August 28, 2026
8-K filed: Other event Filing
—
August 13, 2026
8-K filed: Other event Filing
—
August 6, 2026
Quarterly results filed (8-K) Earnings
—
May 8, 2026
8-K filed: Other event Filing
—
May 5, 2026
Quarterly results filed (8-K) Earnings
—
May 5, 2026
8-K filed: Other event Filing
—
February 24, 2026
Quarterly results filed (8-K) Earnings
—
February 17, 2026
8-K filed: Other event Filing
—
December 19, 2025
8-K filed: Other event Filing
—
December 12, 2025
8-K filed: Other event Filing
—
November 14, 2025
8-K filed: Leadership change Corporate
—
November 5, 2025
Quarterly results filed (8-K) Earnings
—
September 22, 2025
8-K filed: Material agreement, Other event Corporate
—
September 16, 2025
8-K filed: Other event Filing
—
September 8, 2025
8-K/A filed: Other event Filing
—
September 3, 2025
8-K filed: Other event Filing
—
September 2, 2025
8-K filed: Other event Filing
—
August 20, 2025
8-K filed: Leadership change Corporate
—
August 7, 2025
Quarterly results filed (8-K) Earnings
—
May 6, 2025
Quarterly results filed (8-K) Earnings
—
May 1, 2025
8-K filed: Other event Filing
—
February 28, 2025
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM Trial Milestone
Phase 3
November 20, 2024
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants Trial Milestone
Phase 1
November 14, 2023
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval Trial Milestone
Phase 1
November 10, 2023
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM Trial Milestone
Phase 3
August 8, 2023
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants Trial Milestone
Phase 1
July 18, 2023
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Trial Milestone
Phase 3
June 7, 2023
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) Trial Milestone
Phase 3
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.